Vitamin D & Anti-Interleukin Treatment For Respiratory Disease,A promise.

Chemical structure of cholecalciferol, aka vit...
Vitamin D

Respiratory diseases particularly Asthma poses a constant problem to the clinicians as well as to the patients.Vitamin D, in addition to it’s effect on bone found to be effective in treating the respiratory diseases.It has effect on Asthma treatment.The effect of anti-interleukin-5 on the treatment of Asthma is also a novel step.I have quoted summary of two articles below with the name of the authors for the knowledge of all.

Vitamin D and respiratory healthcei_4001 20..25
D. A. Hughes* and R. Norton†
*Institute of Food Research, Norwich Research
Park, and †School of Pharmacy, University of East
Anglia, Norwich, UK
Summary
Vitamin D is now known to be of physiological importance outside of bone
health and calcium homeostasis, and there is mounting evidence that it plays
a beneficial role in the prevention and/or treatment of a wide range of
diseases. In this brief review the known effects of vitamin D on immune
function are described in relation to respiratory health. Vitamin D appears
capable of inhibiting pulmonary inflammatory responses while enhancing
innate defence mechanisms against respiratory pathogens. Population-based
studies showing an association between circulating vitamin D levels and lung
function provide strong justification for randomized controlled clinical trials
of vitamin D supplementation in patients with respiratory diseases to assess
both efficacy and optimal dosage.

………………………………………………………………………………………………………………………

Cytokine and anti-cytokine therapy in asthma: ready for the clinic?cei_3998 10..19
D. Desai and C. Brightling
Institute for Lung Health, Department of
Infection, Inflammation and Immunity,
University of Leicester, Leicester, UK
Summary
Asthma is a common disease with an increasing prevalence worldwide. Up to
10% of these patients have asthma that is refractory to current therapy. This
group have a disproportionate use of health care resources attributed to
asthma, have significant morbidity and mortality and therefore represent an
unmet clinical need. Asthma is a complex heterogeneous condition that is
characterized by typical symptoms and disordered airway physiology set
against a background of airway inflammation and remodelling. The inflammatory
process underlying asthma is co-ordinated by a cytokine network.
Modulating this network with biological therapy presents a new paradigmfor
asthma treatment. Clinical trials undertaken to date have underscored the
complexity of the inflammatory profile and its relationship to the clinical
features of the disease and have raised the importance of safety considerations
related to these novel therapies. T helper type 2 cytokine blockade remains
the most promising strategy, with anti-interleukin-5 reducing asthma
exacerbations. Although anti-cytokine therapy is not yet ready for the clinic,
the long-awaited possibility of new treatments for severe asthma is moving
ever closer.

Reblog this post [with Zemanta]
Advertisements

,

  1. Leave a comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: